Patent Filing

Vision Marine just secured a key patent for its E-Motion™ powertrain. Will this digital fortress be enough to win the e-boating race and calm investor nerves?

With a $9M Middle East deal and a patent fortress, robotics firm XTEND leverages its battle-tested AI to merge its way onto the NYSE at a $1.5B valuation.

A new patent for 3D fibroblast spheroids could revolutionize chronic wound treatment, giving FibroBiologics a key edge in the burgeoning biotech market.

Sila's bold IP lawsuit over its Titan Silicon anode is more than a legal fight; it's a critical test for US tech leadership in the global clean energy race.

A new patent embeds authenticity directly into semiconductor chips, moving beyond blockchain hype to offer a hardware guarantee against forgery for art and beyond.

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

Pluristyx secures a key Japanese patent for its rapid mRNA reprogramming tech, slashing iPSC production time and promising to unlock commercial-scale cell therapy.

A new European patent for 'smart' battery material isn't just tech—it's a strategic move to dominate Europe's high-stakes electrification market.

VisionWave files a patent for a powerful new AI brain. Is SDNN™ a revolution in autonomous defense or a speculative bet on a digital future?

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

Ohio-based Xact Labs secures a key patent for technology that integrates genetic data into pharmacies, aiming to make prescriptions safer and more effective.

Anixa Biosciences secures a key Canadian patent for its novel ovarian cancer vaccine, advancing a new paradigm in cancer prevention for high-risk women.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A secretive Department of War initiative partners a quantum tech firm with special ops experts to deploy a revolutionary battlefield detection system.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.